Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells
Journal for ImmunoTherapy of Cancer · 2024-03 · 12 (3) · e008254
DOI: 10.1136/jitc-2023-008254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.03.2024. Verfasst von Ian-Ian Ng und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Tsinghua-Toyota Joint Research Fund, Tsinghua-Peking University Center for Life Sciences.
Abstract (Originalsprache)
Background
Dendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However, few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds great promise for cancer immunotherapy.
Methods
We observed that type 1 conventional DCs (cDC1s) initiated a distinct transcriptional program during antigen presentation. We used a network-based approach to screen for cDC1-targeting therapeutics. The antitumor potency and underlying mechanisms of the candidate drug were investigated in vitro and in vivo.
Results
Sitagliptin, an oral gliptin widely used for type 2 diabetes, was identified as a drug that targets DCs. In mouse models, sitagliptin inhibited tumor growth by enhancing cDC1-mediated antigen presentation, leading to better T-cell activation. Mechanistically, inhibition of dipeptidyl peptidase 4 (DPP4) by sitagliptin prevented the truncation and degradation of chemokines/cytokines that are important for DC activation. Sitagliptin enhanced cancer immunotherapy by facilitating the priming of antigen-specific T cells by DCs. In humans, the use of sitagliptin correlated with a lower risk of tumor recurrence in patients with colorectal cancer undergoing curative surgery.
Conclusions
Our findings indicate that sitagliptin-mediated DPP4 inhibition promotes antitumor immune response by augmenting cDC1 functions. These data suggest that sitagliptin can be repurposed as an antitumor drug targeting DC, which provides a potential strategy for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
- Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.
- Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, Beijing, China.
- Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China hdtang@tsinghua.edu.cn zengjy321@tsinghua.edu.cn luing@hku.hk.
- Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China hdtang@tsinghua.edu.cn zengjy321@tsinghua.edu.cn luing@hku.hk.
ORCID-Profile: Haidong Tang
Förderung
- National Natural Science Foundation of China
- Tsinghua-Toyota Joint Research Fund
- Tsinghua-Peking University Center for Life Sciences
- Turing AI Institute of Nanjing
- National Key Research and Development Program of China
- National Youth Talent Support Program
- Health and Medical Research Fund of the Research Fund Secretariat, Food and Health Bureau, HKSAR
Zitieren
APA
Ng, I. I., Zhang, J., Tian, T., Peng, Q., Huang, Z., Xiao, K., Yao, X., Ng, L., Zeng, J., & Tang, H. (2024). Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. Journal for ImmunoTherapy of Cancer, 12(3), e008254. https://doi.org/10.1136/jitc-2023-008254
Vancouver
Ng II, Zhang J, Tian T, Peng Q, Huang Z, Xiao K, et al. Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. Journal for ImmunoTherapy of Cancer. 2024;12(3):e008254. doi:10.1136/jitc-2023-008254
BibTeX
@article{Ng2024,
author = {Ng, Ian-Ian and Zhang, Jiaqi and Tian, Tingzhong and Peng, Qi and Huang, Zheng and Xiao, Kaimin and Yao, Xiyue and Ng, Lui and Zeng, Jianyang and Tang, Haidong},
title = {Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {3},
pages = {e008254},
doi = {10.1136/jitc-2023-008254}
}
EUVIMED